Abstract
Anticoagulation with direct oral anticoagulants (DOAC) is becoming increasingly more prominent for stroke prevention in patients with Atrial Fibrillation (AF). Whereas a vitamin k analogue like warfarin would traditionally be used for this; DOACs offer several advantages over warfarin. This review article will provide an overview of the current evidence supporting the use of DOACs for anticoagulation in AF and how a primary care clinician would go about choosing which DOACs to choose and considerations that need to be taken before initiation of the drug. Keywords: Direct Oral Anticoagulants, atrial fibrillation, stroke, primary care, anticoagulation, warfarin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: World Family Medicine Journal /Middle East Journal of Family Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
